许培扬博客分享 http://blog.sciencenet.cn/u/xupeiyang 跟踪国际前沿 服务国内科研

博文

二甲双胍的长寿研究进展 人类120多岁是可能的

已有 7084 次阅读 2015-12-2 16:24 |个人分类:长寿秘诀|系统分类:科研笔记

      参考消息网12月2日报道 英媒称,世界首例抗衰老药将于明年进行临床试验,试验结果可能让阿尔茨海默症和帕金森病等疾病成为遥远的回忆。

  英国《每日电讯报》网站12月1日报道称,科学家现在相信,延缓人的衰老速度并让他们健康活到110多岁、甚至120多岁是有可能的。http://news.sina.com.cn/w/hq/2015-12-02/doc-ifxmaznc5864044.shtml

Trial record 1 of 12 for: Metformin and aging
Previous Study | Return to List | Next Study

Metformin in Longevity Study (MILES)

This study is currently recruiting participants. (seeContacts and Locations)
Verified April 2015 by Albert Einstein College of Medicine of Yeshiva University
Sponsor:
Information provided by (Responsible Party):
Albert Einstein College of Medicine of Yeshiva University
ClinicalTrials.gov Identifier:
NCT02432287
First received: February 24, 2015
Last updated: May 1, 2015
Last verified: April 2015
Purpose
Metformin, an FDA approved first-line drug for the treatment of type 2 diabetes, has known beneficial effects on glucose metabolism. Evidence from animal models and in vitro studies suggest that in addition to its effects on glucose metabolism, metformin may influence metabolic and cellular processes associated with the development of age-related conditions, such as inflammation, oxidative damage, diminished autophagy, cell senescence and apoptosis. As such, metformin is of particular interest in clinical translational research in aging since it may influence fundamental aging factors that underlie multiple age-related conditions. The investigators therefore propose a pilot study to examine the effect of metformin treatment on the biology of aging in humans. Namely, whether treatment with metformin will restore the gene expression profile of older adults with impaired glucose tolerance (IGT) to that of young healthy subjects.

二甲双胍,FDA批准一线药物治疗2型糖尿病,知道有益对葡萄糖代谢的影响。来自动物模型和体外研究的证据表明,除了对葡萄糖代谢的影响,二甲双胍可能影响代谢和细胞过程与年龄有关的症状的发展,如炎症、氧化损伤,减少自噬,细胞衰老和细胞凋亡。因此,二甲双胍是特别感兴趣的临床转化研究衰老,因为它可能会影响多个的基本老化的因素,这是与年龄相关的条件。研究人员因此提出一个试点研究研究二甲双胍治疗的效果在人类衰老的生物学。即,用二甲双胍治疗是否会恢复老年人的基因表达谱与糖耐量受损(IGT)的年轻健康受试者。
(有道同志翻译,只供参考)。

ConditionInterventionPhase
Aging
Drug: Metformin
Drug: Placebo
Phase 4

Study Type:Interventional
Study Design:Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Prevention
Official Title:Metformin in Longevity Study

https://clinicaltrials.gov/ct2/show/NCT02432287?term=Metformin+and++aging&rank=1

 



https://wap.sciencenet.cn/blog-280034-940552.html

上一篇:博客三年以上读者和粉丝就稳定了
下一篇:转载网络文献包括二维码,不能忽略
收藏 IP: 114.111.167.*| 热度|

2 侯成亚 蔡小宁

该博文允许注册用户评论 请点击登录 评论 (0 个评论)

数据加载中...
扫一扫,分享此博文

Archiver|手机版|科学网 ( 京ICP备07017567号-12 )

GMT+8, 2023-2-4 07:15

Powered by ScienceNet.cn

Copyright © 2007- 中国科学报社

返回顶部